Expression Value of Rab10 in Breast Cancer

⁴ Department of Breast Surgery, Yangzhou Maternal and Child Health Hospital Affiliated to Yangzhou University Medica College, 225007 Yangzhou, Jiangsu, China

^*Correspondence: lwg1943@163.com (Weiguang Liu)
^†These authors contributed equally.

Clin. Exp. Obstet. Gynecol. 2023, 50(8), 169; https://doi.org/10.31083/j.ceog5008169

Submitted: 21 February 2023 | Revised: 15 April 2023 | Accepted: 20 April 2023 | Published: 14 August 2023

(This article belongs to the Special Issue Breast Cancer Research and Treatment)

This is an open access article under the CC BY 4.0 license.

Abstract

Background: Rab10 is a small GTPase protein belonging to the Ras superfamily. It is expressed and plays a role in a variety of malignant tumours. However, the expression of Rab10 and its role in breast cancer (BC) prognosis remains unclear. The aim of this study was to analyse the differential expression and prognostic value of Rab10 in BC using bioinformatics techniques and immunohistochemistry in a clinical cohort. Methods: The TIMER2, GEPIA2, and UALCAN databases were used to analyse the correlation between the differential expression of Rab10 and BC. Rab10 and BC prognosis were correlated using the Kaplan–Meier Plotter and UALCAN databases. The expression of Rab10 in BC tissues was detected using immunohistochemistry, and its correlation with the BC clinical cohort was analysed using Chi-squared tests and logistic regression analysis. Results: The expression of Rab10 mRNA identified in BC patients using TIMER2, GEPIA2, and UALCAN databases was higher than that in para-cancerous tissues. Kaplan–Meier plotter and the UALCAN database revealed that increased Rab10 expression was associated with poor prognosis in BC patients. Immunohistochemistry showed that Rab10 was expressed on cell membranes and in cytoplasm of BC tissues. In a clinical cohort, Rab10 expression correlated with histological grade, (human epidermal growth factor receptor 2) HER2 status, and molecular typing. Conclusions: Rab10 can be used as an effective clinical prognostic biomarker for BC.

Keywords

breast cancer

Rab10

prognosis

HER2

Funding

H2021402015/Natural Science Foundation of Hebei Province

20231527/Medical Science Research Project of Hebei Province

Figures

Fig. 1.

Previous article in this issue

Next article in this issue

Fig. 1.

Differential expression of Rab10 in BC cells and BC prognosis. (A) Determination of Rab10 expression levels in different tumour types using TIMER (*p $<$ 0.05, ** p $<$ 0.01, *** p $<$ 0.001). (B) Rab10 is expressed in various cancers and is increased in BC by GEPIA. (C) The UALCAN database analysed Rab10 for high expression in BC. (D) The UALCAN database analysed Rab10 expression in association with poor BC prognosis (p $<$ 0.05). (E,F) In the Kaplan–Meier drawing platform, Rab10 was associated with OS and RFS, and prognosis of the high expression group was poor (p $<$ 0.05). BC, breast cancer; OS, overall survival; RFS, recurrence-free survival.

1 of 2

Clin. Exp. Obstet. Gynecol. Print ISSN 0390-6663 Electronic ISSN 2709-0094